share_log

Xilio Therapeutics To Present Initial Phase 1C Dose Escalation Data For XTX101 In Combination With Atezolizumab In Late-Breaker Poster At SITC 39th Annual Meeting

Xilio Therapeutics To Present Initial Phase 1C Dose Escalation Data For XTX101 In Combination With Atezolizumab In Late-Breaker Poster At SITC 39th Annual Meeting

Xilio Therapeutics将在第39届海丰国际年会上的特别报告海报中展示XTX101联合Atezolizumab的初期1C剂量递增数据
Benzinga ·  10/30 21:25

Xilio Therapeutics To Present Initial Phase 1C Dose Escalation Data For XTX101 In Combination With Atezolizumab In Late-Breaker Poster At SITC 39th Annual Meeting

Xilio Therapeutics将在第39届海丰国际年会上的特别报告海报中展示XTX101联合Atezolizumab的初期1C剂量递增数据

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发